Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

GREY:CLAZF - Post Discussion

Claritas Pharmaceuticals Inc > Nitric Oxide Nasal Spray
View:
Post by indaknownewfie on Feb 27, 2021 5:56pm

Nitric Oxide Nasal Spray

Claritas believes that R-107 has potential to become an effective front-line therapy for patients who contract Covid-19 infection. R-107 is anticipated to be effective against all strains because its mechanism of action is not dependent upon the specifics of the viral structure. The Company believes that R-107 may also have potential as a prophylactic to prevent COVID-19 infection, and the Company intends to also develop R-107 as a nasal spray for this purpose.

Israel is also considering defining the spray as a medical device, NOT A DRUG, she added, (Gilly Regev, CEO Sanotize) which means it could get approval in that country much quicker. Directly from the Global news coverage about the NO spray from SaNOtize.

We know that Claritas has strong Isreali ties so its not far fetched to think our spray could be commercialized quickly

Comment by Scotty on Feb 27, 2021 9:09pm
The company invested in the product it has a licence for believes it's amazing. Well I'm convinced lol.
Comment by Jmk2454 on Feb 27, 2021 10:16pm
Can anyone tell me how long it will take to develop R-107?  The Claritas website says "Claritas will develop R-107 as a therapy . . . "  There is certainly positive data about nitric oxide but will Claritas need to do their own clinical trials?  Is there more information somewhere that I'm missing? 
Comment by indaknownewfie on Feb 27, 2021 10:37pm
My suggestion to you is to go to www.claritaspharma.com and go to the FAQ section . So many questions will be answered for newer investors. 
Comment by Scotty on Feb 27, 2021 10:47pm
God damn lol.
Comment by Scotty on Feb 27, 2021 11:00pm
Take your mind off kly. https://www.youtube.com/watch?v=8LGY68ppqVk You're welcome.
Comment by WORKINMONTANA on Feb 28, 2021 8:25am
Hello Scotty... one of your siblings?   
Comment by WORKINMONTANA on Feb 28, 2021 8:41am
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities